Clinical trials: Chikungunya Fever
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Chikungunya Fever, Quality of Life
Impact of the Chikungunya Outbreak in Reunion Island on the Quality of Life After 10 Years
QoLCHIK study aims at evaluating impact of chikungunya infection on the quality of life of infected people during the 2005-2006 outbreak in Reunion Island and followed in the TELECHIK cohort by comparing scores of SF-36 health…
- Trial name
- QoLCHIK (NCT02901509)
- Where
- France
- Volunteers
- 386 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Leishmaniasis, Leptospirosis
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments).
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever
- Trial name
- SEZAM (NCT06859619)
- Testing
- Peripheral venous blood sample
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Montpellier
Arbovirus Infections, Dengue
Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Dengue, Zika, Chikungunya
- Trial name
- DENWOLUTION (NCT04615364)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Institut Pasteur
Active Immunisation for Chikungunya Virus Infection
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.
A Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age
- Trial name
- CHIKV/II-III (NCT07555392)
- Testing
- BBV87 Chikungunya vaccine
- Where
- 10 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Bharat Biotech International Limited
Chikungunya Virus Infection
Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
This is an observational study with primary data collection, which will combine a prospective safety cohort study and an SCRI study.
- Trial name
- NCT07254702
- Testing
- Live-attenuated CHIKV vaccine VLA1553
- Where
- 3 sites in Brazil
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Virus Infection
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
- Trial name
- NCT04838444
- Testing
- VLA1553
- Where
- 10 sites in United States
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Arbovirus Infections
Spatial Repellents for Aedes-borne Virus Control in Sri Lanka
The primary objective of the study is to demonstrate and quantify the protective efficacy (PE) of a single SR product, in reducing DENV infection and active Aedes-borne virus (ABV) disease in human cohorts.
- Trial name
- AEGIS ABV (NCT05452447)
- Testing
- Transfluthrin
- Where
- 2 sites in Sri Lanka
- Volunteers
- 6,949 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Chikungunya Virus
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to <12 years of age.
- Trial name
- NCT07003984
- Testing
- CHIKV VLP vaccine
- Where
- 15 sites in United States, Philippines and 1 more
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Chikungunya, Chikungunya Fever
A Phase I Study of PepGNP-ChikV in Healthy Volunteers
This is a Phase I, randomized, single-blind, placebo-controlled, study of four separate dose cohorts, with a 42-day interval between each vaccine dose, of a novel Chikungunya Peptide Immunotherapy Vaccine in Healthy Adults (18-60…
- Conditions
- Chikungunya, Chikungunya Fever, Chikungunya Virus Infection, Chikungunya Virus Infections
- Trial name
- NCT07394426
- Testing
- PepGNP-ChikV
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
Chikungunya Fever, Chikungunya Virus
Trial of an Inactivated Chikungunya Virus Vaccine
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 2.5 mcg and 8 mcg of HydroVax-005 CHIKV vaccine given intramuscularly on Day 1 and Day…
- Conditions
- Chikungunya Fever, Chikungunya Virus, Chikungunya
- Trial name
- NCT06669208
- Testing
- HydroVax-005 CHIKV
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Najit Technologies, Inc.
Chikungunya Virus Infection
VLA1553-403 Pregnancy Surveillance Study
This post-marketing, observational study evaluates pregnancy and infant outcomes up to 12 weeks after delivery among women who received the chikungunya vaccine (VLA1553) during pregnancy or within 30 days before their last…
- Trial name
- NCT07414524
- Testing
- Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH
- Where
- 3 sites in Brazil
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Arbovirus Infections, Zika
Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, particularly in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Zika, Dengue, Chikungunya
- Trial name
- VIRIMA (NCT04619823)
- Testing
- Blood sample collection
- Where
- New Caledonia
- Volunteers
- 250 people
- Sponsor
- Institut Pasteur
Chikungunya
Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia
This study has a Phase II with part A and part B and a Phase III with part C. This Adaptive seamless design will prospectively include planned modifications and incorporate both dose selection (parts A and B) and confirmation of…
- Trial name
- IVICHIK001 (NCT04566484)
- Testing
- BBV87 Chikungunya vaccine, Normal Saline
- Where
- 7 sites in Colombia, Costa Rica and 3 more
- Volunteers
- 3,210 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Chikungunya Virus Infection
Chikungunya Virus Detection in Semen
Chikungunya is an arboviral disease transmitted by Aedes mosquitoes, present in intertropical zones and Europe. In August 2024, autochthonous cases appeared on Réunion, followed by a large epidemic.
- Trial name
- CHIKSPERM (NCT06983548)
- Testing
- semen, blood and urine tests
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse
Chikungunya Fever
tDCS and Its Therapeutic Effects in CK Fever
One of the major challenges faced by researchers working in the field of rehabilitation science is the ability to provide integrative approaches to the use of clinical practice.
- Trial name
- NCT02993952
- Testing
- Transcranial Direct Current Stimulation
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte